Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Wu, Ai Luen ^a   Feng, Bo ^a   Chen, Mark Z ^a   Kolumam, Ganesh ^a   Zavala Solorio, Jose ^a   Wyatt, Shelby K ^a   Gandham, Vineela D ^a   Carano, Richard A D ^a   Sonoda, Junichiro ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMMUNOGLOBULIN G; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL FIBROBLAST GROWTH FACTOR RECEPTOR 1 ANTIBODY 1; MONOCLONAL FIBROBLAST GROWTH FACTOR RECEPTOR 1 ANTIBODY 2; PHOSPHATE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE SILENCING; HYPOPHOSPHATEMIA; IN VIVO STUDY; KIDNEY CELL CULTURE; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; BONE DENSITY; CELLS, CULTURED; DNA PRIMERS; FIBROBLAST GROWTH FACTORS; HYPOPHOSPHATEMIA; MALE; MICE; MICE, INBRED C57BL; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84874338054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057322     Document Type: Article

References (42)

1. Razzaque MS, (2009) The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nature reviews Endocrinology 5: 611-619.
2. Quarles LD, (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 8: 276-286.
3. Prié D, Friedlander G, (2010) Genetic disorders of renal phosphate transport. N Engl J Med 362: 2399-2409.
4. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, et al. (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 3087-3094.
5. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98: 6500-6505.
6. Bai X, Miao D, Li J, Goltzman D, Karaplis AC, (2004) Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145: 5269-5279.
7. White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MJ, et al. (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics 26: 345-348.
8. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, et al. (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315.
9. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, et al. (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426.
10. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, et al. (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86: 273-278.
11. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM, (2010) Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86: 267-272.
12. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774.
13. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, et al. (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123.
14. Tomiyama K-i, Maeda R, Urakawa I, Yamazaki Y, Tanaka T, et al. (2010) Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proceedings of the National Academy of Sciences of the United States of America 107: 1666-1671.
15. Brownstein CA, Zhang J, Stillman A, Ellis B, Troiano N, et al. (2010) Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology 151: 492-501.
16. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, et al. (2009) In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB Journal 23: 433-441.
17. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, et al. (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 297: F282-291.
18. Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M, (2011) Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. American journal of physiology Renal physiology 301: F371-377.
19. Liu S, Tang W, Fang J, Ren J, Li H, et al. (2009) Novel regulators of Fgf23 expression and mineralization in Hyp bone. Molecular endocrinology (Baltimore, Md) 23: 1505-1518.
20. Martin A, Liu S, David V, Li H, Karydis A, et al. (2011) Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. The FASEB Journal 25: 2551-2562.
21. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, et al. (2005) Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76: 361-367.
22. Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, et al. (2011) Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med 3: 113ra126.
23. Yamashita T, Konishi M, Miyake A, Inui K-i, Itoh N, (2002) Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. The Journal of biological chemistry 277: 28265-28270.
24. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, et al. (2005) Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. American journal of physiology Endocrinology and metabolism 288: E1101-1109.
25. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T, (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882-889.
26. Bhatia A, Albazzaz M, Espinoza Orias AA, Inoue N, Miller LM, et al. (2012) Overexpression of DMP1 accelerates mineralization and alters cortical bone biomechanical properties in vivo. J Mech Behav Biomed Mater 5: 1-8.
27. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
28. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, et al. (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284: 977-981.
29. Beenken A, Mohammadi M, (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
30. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
31. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, et al. (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38: 1248-1250.
32. Ho AM, Johnson MD, Kingsley DM, (2000) Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289: 265-270.
33. Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, et al. (2001) Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 28: 37-41.
34. Turner N, Grose R, (2010) Fibroblast growth factor signalling: from development to cancer. Nature reviews Cancer 10: 116-129.
35. Brooks AN, Kilgour E, Smith PD, (2012) Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer. Clinical Cancer Research 18: 1855-1862.
36. Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, et al. (2004) Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A 101: 15506-15511.
37. Terauchi A, Johnson-Venkatesh EM, Toth AB, Javed D, Sutton MA, et al. (2010) Distinct FGFs promote differentiation of excitatory and inhibitory synapses. Nature 465: 783-787.
38. Brown A, Courtney C, King L, Groom S, Graziano M, (2005) Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor. Toxicologic Pathology 33: 449-455.
39. Wöhrle S, Bonny O, Beluch N, Gaulis S, Stamm C, et al. (2011) FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 26: 2486-2497.
40. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, et al. (2011) FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis. Journal of the American Society of Nephrology: JASN 22: 1913-1922.
41. Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P, (1999) Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14: 1167-1174.
42. Muller R, Van Campenhout H, Van Damme B, Van Der Perre G, Dequeker J, et al. (1998) Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 23: 59-66.